The US Food and Drug Administration (USFDA) will be lifting the Import Alert 66-40 for Divis Laboratories’ Visakhapatnam unit and moving to close out the Warning letter issued to the company’s Unit-II at Visakhapatnam.
Divis Laboratories focussed on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates. The company in a matter of short time expanded its breadth of operations to provide complete turnkey solutions to the domestic Indian pharmaceutical industry.